The Phase III trial for the Cabometyx and Tecentriq combination treatment met progression-free survival endpoint in metastatic prostate cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,